Perrigo and SCOLR team up for controlled nutrition
products using SCOLR Pharma's proprietary controlled delivery
technology (CDT) drug delivery platform.
The two companies announced their collaboration on Friday. Perrigo is to manufacture the products using SCOLR's technology, and they will bear the store branding of Perrigo's retail customers.
Perrigo's Ernest Schenk told NutraIngredients-USA.com that the company will start with one initial product. At this stage he would not disclose exactly what it is, but it is expected that products will begin shipping in early 2006.
"We believe this agreement with Perrigo validates the strength of our CDT drug delivery platform. Our technology provides the capabilities of the best pharmaceutical controlled delivery systems and applies it to the nutritional market," said Daniel Wilds, president and CEO of SCOLR Pharma.
The company says that CDT removes the need to take repeat doses of drugs, OTC products and nutritional supplements, while still enabling the user to receive the benefits of ingredients contained in a tablet or capsule over a sustained period of time.
This means that the body does not 'dump' excess ingredients that it cannot process at a given time, avoids peaks in serum levels, and prevents mal-absorption.
The CDT platform is based on matrix erosion, changes in gel thickness, electrolyte ionization, and ionic interactions. According to SCOLR, these are "self-correcting systems that lead to carefully controlled erosion as well as a predictable, programmable release of the active ingredient contained in the medicinal core."
"The delivery form is interesting as one-tablet-a-day is increasingly one of the preferred forms for the consumer," said Schenk.
Nutritional products previously launched using SCOLR's technology include glucosamine and chondroitin and vitamin C.
